Investigation Report on China Budesonide Market, 2010-2019

Marketreportsonchina.com presents a report on “Investigation Report on China Budesonide Market, 2010-2019”. In recent years, with the steady growth of global demand, budesonide has occupied an important position in the TOP10 respiratory drugs.

July.,02nd, 2015, Mumbai, India: Market Reports on China presents the report “Investigation Report on China Budesonide Market, 2010-2019”. According to an epidemiological survey, the incidence of respiratory ailments is 16% of the incidence of all diseases.

With the climatic and environmental changes, seasonal asthma has become the main reason for respiratory ailments. According to an epidemiological survey, the incidence of respiratory ailments is 16% of the incidence of all diseases. About 280 million people in the world suffer from different degrees of seasonal asthma, more so in industrialized countries and regions where tobacco consumption is high. 5% of adults and 20% of children there have been attacked by this disease and many of them come down with bronchial asthma induced by chronic cough.

Nearly 300 million people in China contract respiratory ailments, among which over 50 million suffer from cough with an annual growth rate of 4% and 15-20 million asthma.

Budesonide, an adrenocortical hormone, was developed by Astrazeneca in the 1990s. It is mainly used for the treatment of non-glucocorticoid dependent or glucocorticoid-dependent bronchial asthma and chronic obstructive pulmonary disease (COPD). In Jun. 1997, budesonide aerosol got FDA-s approval. In recent years, with the steady growth of global demand, budesonide has occupied an important position in the TOP10 respiratory drugs.

In 1994, China approved the import of budesonide for clinical purposes. After being marketed by Astra (Wuxi) in China in 1995, budesonide develops fast with annual sales rising from CNY 60 million in 2005 to CNY 595 million in 2014 and CAGR reaching up to 29% during the period of 2005-2014. Budesonide enjoys a vast demand in...